Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Home ECG telemonitoring for post-acute myocardial infarction care: a randomized controlled trial
TABI, MEIR , Zeliang, M, Lewis, B, Devamani, Sarah, Levi, D, Rochelin, Sabrina, Solberg, Amanda, Chiraelly, E, Allen, J, Herrmann, J, Ma, Zeliang

Mayo Clinic

European Heart Journal | February 4, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.2157 Get It

Abstract Background Acute myocardial infarction (AMI) patients face a substantial risk of cardiovascular events and rehospitalization. The impact of the SmartHeart 12-lead ECG telemedicine device on healthcare utilization has not been tested in a US randomized trial. Methods Patients with AMI were randomized at discharge to standard of care without (control group) or with the SmartHeart 12-lead ECG device (intervention group). The primary endpoint was the rate of emergency department (ED) visits, hospital readmissions, and any cardiovascular testing from discharge to 90 days of follow-up. Results The primary endpoint was reached in 57/96 patients (59.4%) in the control group and 53/84 patients (63.1%) in the intervention group (p = 0.61). However, in the intervention group, only 24.7% of patients complied with 2 follow-up training SmartHeart 12-lead ECG transmissions after discharge, and only 21.6% used the device thereafter. In patients who did use the device after training, 38.2% were advised by the study team to refer to the ED, each time with a significant clinical presentation: 7 patients had chest pain (3 AMI); 2 atrial flutter/fibrillation; 1 ventricular fibrillation. Among device users, ED presentations were lower in the intervention (2/25, 8.0%) than in the control (28/96, 29.2%) group (p = 0.04, Figure 1). Conclusion In this US-based trial, the utilization of the SmartHeart 12-lead ECG device was low, which compromised the primary outcome analysis. Decreased compliances resulted in more ED visits. Figure 1: Cumulative incidence of ED visits in controls and per protocol device use compliant patients.Cumulative incidence of ED visits in con
Addressing recurrent pericarditis: assessing patient and professional education needs
Klein, A, Wang, T, Weber, B N, Abbate, A, Kohnstamm, S, Luis, S A, Cremer, P, Al-Kazaz, M, Shah, D, Wang, L, Sabet, Amin , Tadwalkar, R, Participants, A H A Addressing Recurrent Pericarditis Initiative, Staff, A H A Addressing Recurrent Pericarditis, Cremer, Paul , Cremer, Paul C , Klein, Allan L. , Wang, T, Weber, Brittany , Abbate, Antonio , Salik, Jonathan R. , Kohnstamm, Sarah, Luis, S A, Al‐Kazaz, Mohamed

Mayo Clinic

European Heart Journal | February 4, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.4512 Get It

Abstract Background Nearly 40,000 people in the U.S. experience recurrent pericarditis with up to 90% of cases having no identifiable cause, often making the journey to diagnosis arduous. Understanding the challenges that patients and health care professionals (HCP) face will help address gaps and barriers in patient diagnosis and care. In addition, the lack of U.S. based guidelines for recurrent pericarditis clinical care, coupled with the time lapse from the last published European guideline, has created an opportunity to discover workflow solutions for U.S. based healthcare professionals. Purpose The American Heart Association’s (AHA) Addressing Recurrent Pericarditis Initiative is a three-year effort utilizing a quality improvement approach to address gaps/barriers in patient care, educate HCPs, and develop patient education resources to improve diagnosis, treatment, and quality of life. To accomplish this, the lived experiences and challenges patients face on their journey to diagnosis was integrated into the qualitative research process. Methods To assess quality improvement opportunities, the AHA engaged HCPs with recurrent pericarditis experience from 15 diverse health systems to participate in a learning collaborative strategy for quality improvement and implementation to share successful strategies, provide input on professional education topics, and participate in process mapping. Data collection strategies include 1:1 consultations, quarterly learning collaborative calls, surveys and questionnaire completion. To assess patient education needs, the AHA Market Research Team held 1-hour video interviews with ten diverse patients. Results AHA-led HCP interviews produced process maps of clinical workflows and identified opportunities for standardization to improve clinical workflow and patient outcomes (Figure 1). From these data collection methods, preliminary results include care coordination across clinical settings, exploring treatment options, standardization of follow-up cadence, and provider awareness of misdiagnoses/underdiagnosis rates. The patient interviews revealed that there is a lack of symptom recognition, persistent rate of misdiagnosis, delay in accurate diagnosis and treatment, and discrepancies in diagnosis and treatment for various demographics including female and younger adult patients (Figure 2). Conclusion(s) In Year 2 of this three-year initiative, we will continue to refine identified areas of opportunities to improve patient outcomes by creating and disseminating educational materials and launch awareness campaigns, while also producing a national education series for HCPs that provide guidance for system-level quality improvement to emphasize consistency in care and reductions in health inequities. Key findings from this study highlight the care coordination involved in the treatment of patients with recurrent pericarditis and the need to provide multidiscipline educational approaches to achieve this goal.Figure. 1 Summary of care pathway Figure. 2 Summary of patient interviews
Adoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States
Leapman, Michael S., Long, Jessica B., Westvold, Sarah , Rabil, Maximilian , Sprenkle, Preston C. , Kim, Isaac Y., Spilberg, Gabriela , Saperstein, Lawrence, Fallah, Jaleh , Suzman, Daniel L. , Lerro, Catherine, Xu, Jianjin , Rivera, Donna R. , Karnes, R. Jeffrey, Dinan, Michaela, Mitchell, Aaron Philip , Wang, S, Gross, Cary P. , Leapman, Michael , Westvold, Sarah J. , Leapman, Michael S , Dinan, Michaela A , Mitchell, Aaron P , Wang, Shi-Yi , Ma, Xiaomei , Rivera, Donna R. , Kluetz, Paul Gustav , Karnes, R. Jeffrey , Dinan, Michaela A. , Kunst, Natalia , Ma, Xiaomei

Mayo Clinic

JCO Oncology Practice | February 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/op-25-00617 | PMID 41632928 Get It

PURPOSE Despite evidence of diagnostic accuracy but unclear long-term clinical benefit, national utilization patterns of prostate-specific membrane antigen positron emission tomography (PSMA-PET) are undefined. METHODS We conducted a serial cross-sectional study to evaluate the use of PET imaging among commercial insurance beneficiaries with prostate cancer using administrative claims from deidentified Blue Cross Blue Shield Axis database. Eligible patients included prevalent and incident prostate cancer cases. We calculated the proportions undergoing PET imaging in semiannual periods from January 1, 2016, through December 31, 2024. We examined the association between regional-level contextual sociodemographic and health care characteristics, and regional use of PSMA-PET imaging in 2024. RESULTS A total of 514,750 male beneficiaries age 40-89 years with prostate cancer were identified between 2016 and 2024. The proportion of individuals with prostate cancer undergoing PET imaging increased from 4.5 [95% CI, 4.1 to 4.9] per 1,000 in the first half of 2016 to 77.6 (95% CI, 76.2 to 79.1) per 1,000 in the second half of 2024, P < .001. Increases in PET were driven by uptake of PSMA-PET following approval in 2021, which increased from 0.8 (95% CI, 0.6 to 0.9) per 1,000 in the second half of 2021 to 77.0 (95% CI, 75.5 to 78.5) per 1,000 in the second half of 2024, P < .001. PSMA-PET use in 2024 was higher in regions with greater education (99.3 v 114.6 per 1,000 in lowest [Q1] v highest [Q4] educated) and income (95.4 v 112.3 per 1,000 in Q1 v Q4 income) measures, P < .001. CONCLUSION PSMA-PET was rapidly incorporated into clinical practice among commercial insurance beneficiaries with prostate cancer with higher adoption in geographic regions with higher income and education.
Functional genomics identifies therapeutic options, biomarkers, and resistance mechanisms for high-grade gliomas
Lin, Wan-Hsin, Kosari, Farhad , Smadbeck, James B. , Barrett, Michael T. , Feathers, Ryan, Hall, Jamie, Sadeghian, Dorsay , Johnson, Sarah H. , Harris, Faye R. , Berry, Taylor, McCune, Alexa, Murphy, Stephen James, Kinsella, Lindsey, Ensign, Shannon P. Fortin, Yang, Lin , Emanuel, Angela, Jones, Leila A., Schaefer-Klein, Janet, Ida, Cristiane M., Sherman, Wendy, Porter, Alyx B. , Rosenfeld, Steven, Kizilbash, Sani H., Jaeckle, Kurt A. , Mrugala, Maciej M., Borad, Mitesh, Bendok, Bernard R., Quiñones-Hinojosa, A., Cheville, John C. , Vasmatzis, George , Anastasiadis, Panos Z. , Ensign, Shannon P. Fortin , Mansfield, Aaron S , Ensign, Shannon P. Fortin , Sotiriou, Sotiris , Haydu, Lauren E. , Moniz‐Garcia, Diogo , Ida, Cristiane M., Salomao, Marcela , Kizilbash, Sani H. , Mrugala, Maciej M., Mansfield, Aaron S. , Borad, Mitesh J. , Bendok, Bernard R. , Burns, Terry C. , Quiñones‐Hinojosa, Alfredo

Mayo Clinic

No container title available | February 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.01.701806 | PMID 41676502 Get It

Abstract High-grade gliomas (HGGs) are aggressive tumors with poor outcomes and limited treatment options. Here, we combined genomic and transcriptomic tumor profiling with drug testing in a patient-derived 3-dimensional culture model to identify individualized treatments and predictive biomarkers. Activity of single agents targeting frequently dysregulated glioma pathways was relatively poor ex vivo and generally reflected historical patient data. However, compounds targeting PI3K, epigenetic, and survival/senescence signaling were effective in some cases. Drug sensitivity correlated with transcriptional rather than genomic features and suggested heterogeneity as a resistance mechanism. Bromodomain and extraterminal domain inhibition was particularly effective in tumors enriched in the mesenchymal transcriptional subtype, promoted proneural transition, and was overcome by upregulated PI3K signaling. Notably, combinations were largely effective, with 6 strategies exhibiting stronger efficacy than corresponding single agents in most cases (58-77%). This study identifies HGG vulnerabilities and associated biomarkers, resistance mechanisms, and effective combination strategies that warrant further clinical validation. Graphical Abstract
Characterizing early behavioral and social–emotional problems in young children with SCN1A + Dravet syndrome: Findings from the E
Scheffer, Ingrid E., Perry, M. Scott, Sullivan, Joseph , Boronat, Susana , Wheless, J. W., Brunklaus, Andreas , Laux, Linda C, Patel, Anup D. , Roberts, Colin, Dlugos, Dennis J., Holder, Deborah , Lallas, Matt, Phillips, Steven, Segal, Eric , Lal, Dennis , Wirrell, Elaine, Zuberi, Sameer M., Shaffer, Rebecca, Wojnaroski, Mary , Christensen, Sarah , James, Emma S., Huang, Norman, Gofshteyn, Jacqueline S. , Scheffer, Ingrid E. , Wheless, James W. , Shaffer, Rebecca C. , Scheffer, Ingrid E , Perry, Michael Scott , Wheless, James W , Dlugos, Dennis , Knupp, Kelly G , Phillips, Steven , Segal, Eric , Lal, Dennis , Wirrell, Elaine C , Zuberi, Sameer M , Shaffer, Rebecca , Wojnaroski, Mary , Berl, Madison , James, Emma S , Vila, Maria Candida , Gofshteyn, Jacqueline S , Rico, Salvador , Patel, Anup D , Brunklaus, Andreas , Laux, Linda , Roberts, Colin, Dlugos, Dennis , Knupp, Kelly G. , Phillips, Steven , Wirrell, Elaine , Zuberi, Sameer M. , Berl, Madison M. , James, Emma S. , Huang, Norman, Rico, Salvador

Mayo Clinic

Epilepsia | February 2, 2026 | Volume: 67 | Issue: 5 | Pages: 2463-2479

10.1002/epi.70127 | PMID 41627953 Get It

Abstract Objective Dravet syndrome (DS) is the prototypic developmental and epileptic encephalopathy, characterized by drug‐resistant seizures, developmental slowing, and many other morbidities. Detailed characterization of behavioral phenotypes and social–emotional skill development are limited. Methods We prospectively assessed behavioral and social–emotional problems in the ENVISION natural history study (NCT04537832) of children with DS associated with SCN1A pathogenic variants ( SCN1A + DS) enrolled at <5 years of age. Assessments every 3 months for up to 2 years included the Child Behavior Checklist (CBCL), Strengths and Difficulties Questionnaire (SDQ), Brief Infant‐Toddler Social and Emotional Assessment (BITSEA), and Vineland Adaptive Behavior Scales, 3rd Edition (VABS‐3). Results Fifty‐eight children with DS enrolled at 16 sites worldwide. Problematic behaviors—inattention, aggressive or oppositional behaviors, and withdrawn and autistic behaviors—began before age 3 years, became more evident with age, and were clinically significant in many children by age 3–4 years. CBCL Total, Externalizing, and Internalizing Problems T‐scores rose by approximately 3 points per year, and BITSEA Problem scale scores increased by 2.3 points annually ( p = .002). SDQ Hyperactivity scores worsened over time ( p = .013), whereas emotional difficulties remained stable. VABS‐3 Socialization domain scores, which were already more than 1 SD below the normative mean at baseline, decreased further, particularly in younger participants. Correlation analyses showed that poorer communication abilities were associated with increased problematic behaviors ( R = −.55 for CBCL Total Problems and VABS‐3 Communication scores). Mixed‐effects modeling identified age as the strongest predictor of worsening behavioral outcomes. Significance We found that behavioral and social–emotional problems are inherent components of DS that present in toddlerhood and worsen throughout early childhood. This highlights the need to diagnose and manage these issues early. Targeted therapy may alleviate the wide‐ranging morbidities that are intrinsic to DS, including the social–emotional and behavior problems that frequently emerge.
Sex and anticitrullinated protein antibodies modify the relationship between inflammation and cardiovascular risk in rheumatoid arthritis
Karpouzas, George , Pascual-Ramos, Gonzalez-Gay, Miguel A, Misra, Durga P, Rantapää-Dahlqvist, Solbritt, Sfikakis, Petros , Dessein, Patrick, Hitchon, C., Galarza-Delgado, D. Á. , Riel, Piet Van, Hauge, Ellen-M., Kitas, George D, González‐Gay, Miguel Á. , Rantapää‐Dahlqvist, Solbritt , Misra, Durga Prasanna , Karpouzas, George Athanasios , Pascual-Ramos, Virginia , Gonzalez-Gay, Miguel A , Misra, Durga Prasanna , Myasoedova, Elena , Rantapää-Dahlqvist, Solbritt , Dessein, Patrick , Galarza-Delgado, Dionicio Angel , Semb, Anne Grete , Hauge, Ellen-M , Pascual‐Ramos, Virginia , Myasoedova, Elena , Dessein, Patrick H , Hitchon, Carol , Semb, Anne Grete , Hauge, Ellen‐Margrethe , Ormseth, Sarah R.

Mayo Clinic

RMD Open | February 2, 2026 | Volume: 12 | Issue: 1 | Pages: e006420

10.1136/rmdopen-2025-006420 | PMID 41629127 Get It

Objectives Female sex and anticitrullinated protein antibodies (ACPA) are associated with higher disease activity in rheumatoid arthritis (RA). Since disease-related inflammation is linked to cardiovascular risk, we explored whether sex and ACPA influenced the association between disease activity at study entry and cardiovascular risk in established RA. Methods We evaluated 4008 patients with prevalent RA from an international observational cohort enrolled between 1985 and 2012. Outcomes included major adverse cardiovascular events (MACE: cardiovascular death, myocardial infarction and stroke) and ischaemic cardiovascular events (iCVE: MACE, angina, revascularisation, transient ischaemic attack and peripheral arterial disease). Follow-up accrued from enrolment until the first event or censoring. Multivariable Cox models stratified by centre risk evaluated disease activity, sex, ACPA and their interactions. Results We documented 193 MACE and 299 iCVE. Disease activity and sex were associated with MACE (all p≤0.017) and iCVE (p≤0.005) but ACPA was only associated with MACE (p=0.043). A three-way interaction on MACE (p=0.034) but not iCVE was noted. Among ACPA-negative patients, disease activity was associated with MACE in males (HR 1.57 (95% CI 1.14 to 2.16)) but not females (p-for-interaction=0.022). Among ACPA-positive patients, neither the disease activity x sex interaction (p=0.929), nor main effect of disease activity on MACE (p=0.124) was significant, but male sex was (HR 1.61 (95% CI 1.15 to 2.27)). Among females, neither disease activity x ACPA interaction (p=0.523) nor disease activity (p=0.319) was significant for MACE, but ACPA was (HR 1.57 (95% CI 1.02 to 2.42)). Conclusions The effect of disease activity at enrolment on cardiovascular risk in prevalent RA varies across patient groups with different sex and ACPA characteristics.
Recommendations for Advanced Practice Provider Postgraduate Training Programs in the United States: A Work Product of the Advanced Practice Provider Postgraduate Training Task Force of the Society of Critical Care Medicine
Ricker, Melissa, Abide, Aimee, Bakshi, Vishal, Bane, Tina, Bhullar, Simrit K., Byrd, Cindy , Fuller, Todd E., Gunville, Cameron, Hogan, Brett , Nugent, Katherine Lyn, Pandya, Komal , Peacock, Sarah, Pisa, Michael, Meissen, Heather H., McLaughlin, Diane , Boling, Bryan , Farley, Thomas, Newman, Christopher, Nugent, Katherine Lyn, Peacock, Sarah, Meissen, Heather

Mayo Clinic

Critical Care Medicine | January 30, 2026 | Volume: 54 | Issue: 4 | Pages: 825-835

10.1097/ccm.0000000000007061 | PMID 41615242 Get It

OBJECTIVES: The overall goal of this work is to discuss the various topics associated with critical care advanced practice provider (APP) postgraduate training programs and provide resources for new, developing and existing programs. DESIGN: Three rounds of voting until consensus achieved. SETTING: Electronic surveys, followed by virtual meeting. SUBJECTS: Critical care APPs, physicians, a pharmacist, and a nurse were also included to ensure multidisciplinary representation. All subjects resided and practiced in the United States with a history of education scholarship or post-graduate training leadership. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: The workgroup included 14 APPs (ten nurse practitioners and four physician associates), three physicians, one pharmacist, and one registered nurse from 14 institutions across the United States. The workgroup identified six areas of concentration: administration, audience, program structure, curriculum, procedural competence, and accreditation. A survey was generated and employed in three rounds. The first two rounds of voting were completed anonymously, the third round was completed as a live meeting until consensus recommendations, defined as 75% agreement or more, were achieved. CONCLUSIONS: Expert consensus was used to generate consensus recommendations for critical care postgraduate training programs based upon 3 rounds of voting.
Home electrocardiogram telemonitoring for post-acute myocardial infarction care: a randomized controlled trial
TABI, MEIR , Ma, Zeliang, Lewis, Bradley, Devamani, Sarah, Rochelin, Sabrina, Solberg, Amanda, Chiarelly, Elaine, Allen, Joy, Herrmann, Joerg, Tabi, Meir , Herrmann, Joerg , Lewis, Bradley, Allen, J, Herrmann, Joerg

Mayo Clinic

European Heart Journal Open | January 29, 2026 | Volume: 6 | Issue: 1 | Pages: No page available

10.1093/ehjopen/oeag014 | PMID 41788509 Get It

Abstract Aims Acute myocardial infarction (AMI) patients face a substantial risk of cardiovascular events and rehospitalization. The impact of the SmartHeart 12-lead electrocardiogram (ECG) telemedicine device on healthcare utilization has not been tested in a US randomized trial. Methods and results Patients with AMI were randomized at discharge to standard of care without (control group) or with the SmartHeart 12-lead ECG device (intervention group). The primary endpoint was the rate of emergency department (ED) visits, hospital readmissions, and any cardiovascular testing from discharge to 90 days of follow-up. The primary endpoint was reached in 57 (59%) patients in the control group and 53 (63%) patients in the intervention group (P = 0.61). However, in the intervention group, only 30% of patients complied with two follow-up training SmartHeart 12-lead ECG transmissions after discharge, and only 24% used the device thereafter. Among device users, ED presentations were lower in the intervention group than in the control group (8.0% vs. 29%, P = 0.04). In all patients advised to present to the ED upon device use (38%), a clinically relevant cardiovascular diagnosis was made. One patient survived a ventricular fibrillation cardiac arrest as advised to present to ED urgently after device use. Conclusion In this US-based RCT, there were no significant differences in the primary outcome in the intention-to-treat analysis. However, according to per-protocol analysis, proper use of the SmartHeart ECG device with 24/7 telemedicine support reduced inappropriate and increased appropriate ED presentations after hospitalization for AMI.
A Phosphorylation Switch Governs KIF11’s Mechanical Output During Mitosis
Šemić, Amila , Reddy, Babu Jn, Muretta, Joseph M. , Vandal, Sarah E. , Thompson, Alex F. , Fonseca, Cindy L., Rosenfeld, Steven S. , Gross, Steven P. , Stumpff, Jason , Reddy, Babu J.N.

Mayo Clinic

No container title available | January 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.23.700875 | PMID 41648279 Get It

Abstract The kinesin-5 motor protein KIF11 is crucial for mitotic spindle assembly, driving the separation of spindle poles through microtubule sliding. Src-family kinases phosphorylate KIF11 at multiple tyrosine residues within its motor domain, but the mechanistic consequences of these modifications remain unclear. Here, we dissect the role of phosphorylation at Y211 using phospho-mimetic (Y211E) and non-phosphorylatable mutants (Y211F) in biochemical, biophysical, and cellular assays. Optical trapping and Förster resonance energy transfer (FRET) analyses reveal that Y211 phosphorylation slows neck-linker docking, reducing motor velocity and force generation under load. In human cells, Y211E expression impairs bipolar spindle formation and decreases spindle pole separation velocity, while Y211F shortens steady-state spindle length. Fluorescence recovery after photobleaching (FRAP) analyses show that Y211E accelerates motor turnover on spindle microtubules, consistent with the mutant motor’s heightened load sensitivity. Together, these findings support a model in which Src-mediated phosphorylation at Y211 acts as a rheostat to tune KIF11 mechanochemistry and spindle assembly dynamics, linking cancer-relevant kinase signaling to mitotic force generation.